Infections in pre-RA: a cause or a consequence? Dr. Aurelie Najm ( @AurelieRheumo) discusses oral presentation abstract #0535 from #ACR22. https://t.co/ajI2zo4KRA https://t.co/cHkzNshVcn

• https://bit.ly/3tLxmqy

Proposed Cancer Screening for Inflammatory Myositis Patients 11/12's plenary session features a novel proposal on how and which patients with Idiopathic Inflammatory Myopathy (IIM) should be screened for cancer. https://t.co/uMhJu6eQt1 https://t.co/JeeeGadP4d

• https://bit.ly/3EPy6kZ

#ACR22 Appraisal, Praise & Critique Dr. Cush talks ACR22, the highs and the lows. https://t.co/NoRqvFaBKl https://t.co/0b5IlAojVq

• https://bit.ly/3Orff2N

Exciting Data for SLE: Plenaries from #ACR22 Dr. Michael Putman ( @EBRheum ) shares SLE updates shared at #ACR22. https://t.co/e6tCwLdHMS https://t.co/u7yoE4T9Zs

• https://bit.ly/3GuO85c

Dual target blockade may be better than one in SLE Dr. Yusof ( @Yuz6Yusof) discusses abstracts #L07 and #1001 presented at #ACR22. https://t.co/0SzQAorzZy https://t.co/fZ6CpFNSWI

• https://bit.ly/3UNPImM

Lupus Topic Panel Join RheumNow to recap the best and most interesting data presented at #ACR22 in the area of SLE. Panelists: @KDAO2011 @bella_mehta @Yuz6Yusof @ericdeinmd @EBRheum @RHEUMarampa @Janetbirdope https://t.co/7oUZcQK27U https://t.co/1JClivUJpk

• https://bit.ly/3hQ1nTz

2022 ACR/EULAR Classification Criteria for GCA Dr. Michael Putman discusses interesting take-home messages from the Vasculitis Investigators Meeting at ACR22 Convergence regarding the 2022 ACR/EULAR Classification Criteria for GCA. https://t.co/FL9FGhWcxB https://t.co/JKi7Nn4O2O

• https://bit.ly/3ElZJRl

Avoid Abatacept in RA patients with a history of cancer? Dr. Richard Conway ( @RichardPAConway ) discusses abstracts #0267 and #0255 presented at #ACR22. https://t.co/1lC33XlBt7 https://t.co/ttUQaTVF43

• https://bit.ly/3ggXPcy

Anifrolumab shows long-term promise in patients with lupus Researchers report positive results from the first placebo-controlled long-term trial of anifrolumab—a human monoclonal antibody that targets the type I IFN receptor—in patients with lupus. https://t.co/IlgEUKkMOv https://t.co/kpSt61d5Qx

• https://bit.ly/3EoB6Dx

Effect of voclosporin in class V lupus nephritis Dr. Yusof ( @Yuz6Yusof) discusses abstract 0355 presented at #ACR22. Abstract 0355: Long-term Use of Voclosporin in Patients with Class V Lupus Nephritis: Results from the AURORA 2 Continuation Study https://t.co/sH04dhBskS https://t.co/mUOrJKdYBF

• https://bit.ly/3GqHf4I